This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, N.-K. Articles by Inn, K.-S. Search for Related Content PubMed PubMed Citation Articles by Lim, N.-K. Articles by Inn, K.-S.

An Anthrax Lethal Factor-Neutralizing Monoclonal Antibody Protects Rats before and after Challenge with Anthrax Toxin

R&D Center, Aprogen, Inc., Bio Venture Center #311, Korea Research Institute of Bioscience and Biotechnology, 52 Eoeun-dong, Yuseong-gu, Daejon 305-333, South Korea,¹ Laboratory of Antibody Engineering, Korea Research Institute of Bioscience and Biotechnology, 52 Eoeun-dong, Yuseong-gu, Daejon 305-333, South Korea²

Received 9 May 2005/ Returned for modification 28 May 2005/ Accepted 23 June 2005

Lethal factor (LF) is a component of anthrax lethal toxin (LeTx). We generated anti-LF murine monoclonal antibodies (MAbs) that show LeTx-neutralizing activity in vitro and in vivo. Anti-LF MAbs were generated by immunization with recombinant LF, and the MAbs showing LeTx-neutralizing activity in vitro were selected. Two MAbs with the highest affinities, 5B13B1 (dissociation constant [K_d], 2.62 nM) and 3C16C3 (K_d, 8.18 nM), were shown to recognize the same or closely overlapping epitopes on domain III of LF. The 50% inhibitory concentration of 5B13B1 (0.21 µg/ml) was approximately one-third that of 3C16C3 (0.63 µg/ml) in the in vitro LeTx-neutralization assay. The 5B13B1 antibody, which had the highest neutralizing activity, provided perfect protection against LeTx challenge in an in vivo LeTx neutralization assay using Fisher 344 rats. In addition, the antibody showed pre- and postexposure prophylactic effects in the animal experiments. This is the first report that an MAb binding to domain III of LF has neutralizing activity against LeTx. The 5B13B1 antibody may be useful in prophylaxis against anthrax poisoning.

Editor: J. D. Clements

This article has been cited by other articles:

• Albrecht, M. T., Li, H., Williamson, E. D., LeButt, C. S., Flick-Smith, H. C., Quinn, C. P., Westra, H., Galloway, D., Mateczun, A., Goldman, S., Groen, H., Baillie, L. W. J. (2007). Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax. Infect. Immun. 75: 5425-5433 [Abstract] [Full Text]  
• Staats, H. F., Alam, S. M., Scearce, R. M., Kirwan, S. M., Zhang, J. X., Gwinn, W. M., Haynes, B. F. (2007). In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity. Infect. Immun. 75: 5443-5452 [Abstract] [Full Text]  
• Pelat, T., Hust, M., Laffly, E., Condemine, F., Bottex, C., Vidal, D., Lefranc, M.-P., Dubel, S., Thullier, P. (2007). High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation. Antimicrob. Agents Chemother. 51: 2758-2764 [Abstract] [Full Text]  
• Sherer, K., Li, Y., Cui, X., Eichacker, P. Q. (2007). Lethal and Edema Toxins in the Pathogenesis of Bacillus anthracis Septic Shock: Implications for Therapy. Am. J. Respir. Crit. Care Med. 175: 211-221 [Abstract] [Full Text]